The pharmacology of new antiepileptic drugs: Does a novel mechanism of action really matter?

CNS Drugs

Volumn 25, Issue 11, 2011, Pages 907-912

  Perucca, Emilio ^a  

^a C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

Author keywords

Antiepileptic drugs; Epilepsy; Pharmacology

Indexed keywords

5,5 DIPHENYLBARBITURIC ACID; ACETAZOLAMIDE; ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; BRIVARACETAM; CALCIUM CHANNEL AFFECTING AGENT; CARBAMAZEPINE; ESLICARBAZEPINE ACETATE; ETHOSUXIMIDE; FELBAMATE; GABAPENTIN; GANAXOLONE; HARKOSERIDE; ICA 105665; LAMOTRIGINE; NEW DRUG; OXCARBAZEPINE; PERAMPANEL; PHENOBARBITAL; PHENYTOIN; POTASSIUM CHANNEL STIMULATING AGENT; PREGABALIN; RETIGABINE; RUFINAMIDE; SODIUM CHANNEL BLOCKING AGENT; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIGABATRIN; VOLTAGE GATED SODIUM CHANNEL; ZONISAMIDE;

ABSENCE; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM DISEASE; COMORBIDITY; DIZZINESS; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG MECHANISM; DRUG RESEARCH; DRUG TOLERABILITY; EPILEPSY; FOCAL EPILEPSY; GABAERGIC SYSTEM; HUMAN; HYPONATREMIA; LENNOX GASTAUT SYNDROME; METABOLIC ACIDOSIS; MICTURITION DISORDER; MOTOR COORDINATION; NEPHROLITHIASIS; PARESTHESIA; PATHOPHYSIOLOGY; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SEIZURE; SEVERE MYOCLONIC EPILEPSY IN INFANCY; SIDE EFFECT; TREATMENT INDICATION; TREATMENT RESPONSE; WEIGHT GAIN;

ANTICONVULSANTS; DRUG DISCOVERY; DRUG INDUSTRY; EPILEPSY; HUMANS; TREATMENT OUTCOME;

EID: 80555129629     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11587900-000000000-00000     Document Type: Review

References (44)

1. Kale R, Perucca E. Revisiting phenobarbital for epilepsy. BMJ 2004 Nov 20; 329 (7246): 1199-200 (Pubitemid 39551441)
2. Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults. Lancet Neurol 2011 May; 10 (5): 446-56
3. Perucca E, French J, Bialer M. Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol 2007 Sep; 6 (9): 793-804 (Pubitemid 47243712)
4. Fattore C, Perucca E. Novel pharmacotherapies for epilepsy. Drugs. In press
5. Perucca E. An introduction to antiepileptic drugs. Epilepsia 2005; 46 Suppl. 4: 31-7 (Pubitemid 40847381)
6. Rogawski MA, Lö scher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004 Jul; 5 (7): 553-64 (Pubitemid 38868551)
7. Errington AC, Stöhr T, Heers C, et al. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 2008 Jan; 73 (1): 157-69 (Pubitemid 350294207)
8. Rundfeldt C. The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells. Eur J Pharmacol 1997 Oct 8; 336 (2-3): 243-9 (Pubitemid 27464871)
9. Hanada T, Hashizume Y, Tokuhara N, et al. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia 2011 Jul; 52 (7): 1331-40
10. Goa KL, Ross SR, Chrisp P. Lamotrigine: a review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1993 Jul; 46 (1): 152-76 (Pubitemid 23232410)
11. Cheung H, Kamp D, Harris E. An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels. Epilepsy Res 1992 Nov; 13 (2): 107-12
12. Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res 2010 Dec; 92 (2-3): 89-124
13. White HS, Smith MD, Wilcox KS. Mechanisms of action of antiepileptic drugs. Int Rev Neurobiol 2007; 81: 85-110
14. Rheims S, Perucca E, Cucherat M, et al. Factors determining response to antiepileptic drugs in randomized controlled trials: a systematic review and meta-analysis. Epilepsia 2011 Feb; 52 (2): 219-33
15. Baulac M, Leon T, O'Brien TJ, et al. A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial-onset seizures. Epilepsy Res 2010 Sep; 91 (1): 10-9
16. Schmidt D. Antiepileptic drug discovery: does mechanism of action matter? Epilepsy Behav 2011 Aug; 21 (4): 342-3
17. Beyenburg S, Stavem K, Schmidt D. Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis. Epilepsia 2010 Jan; 51 (1): 7-26
18. Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006 Jul; 47 (7): 1094-120 (Pubitemid 44086745)
19. Perucca E, Gram L, Avanzini G, et al. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998 Jan; 39 (1): 5-17 (Pubitemid 28116836)
20. Crumrine PK. Management of seizures in Lennox-Gastaut syndrome. Pediatr Drugs 2011 Apr 1; 13 (2): 107-18
21. Frank LM, Enlow T, Holmes GL, et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia 1999 Jul; 40 (7): 973-9 (Pubitemid 29316053)
22. Vohora D, Saraogi P, Yazdani MA, et al. Recent advances in adjunctive therapy for epilepsy: focus on sodium channel blockers as third-generation antiepileptic drugs. Drugs Today (Barc) 2010 Apr; 46 (4): 265-77
23. Özkara Ç, Vigevano F. Immuno-and antiinflammatory therapies in epileptic disorders. Epilepsia 2011 May; 52 Suppl. 3: 45-51
24. Klepper J. GLUT1 deficiency syndrome in clinical practice. Epilepsy Res. Epub 2011 Mar 5
25. Mullen SA, Marini C, Suls A, et al. Glucose transporter 1 deficiency as a treatable cause of myoclonic astatic epilepsy. Arch Neurol. Epub 2011 May 9
26. Guerrini R, Dravet C, Genton P, et al. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 1998 May; 39 (5): 508-12 (Pubitemid 28221807)
27. Yu FH, Mantegazza M, Westenbroek RE, et al. Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci 2006 Sep; 9 (9): 1142-9 (Pubitemid 44306307)
28. Brodie M, Covanis T, Gil-Nagel A, et al. Antiepileptic drug therapy: does mechanism of action matter? Epilepsy Behav 2011 Aug; 21 (4): 331-41
29. De Groot M, Aronica E, Heimans JJ, et al. Synaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma. Neurology 2011 Aug 9; 77 (6): 532-9
30. Besag FM, Berry DJ, Pool F, et al. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? Epilepsia 1998 Feb; 39 (2): 183-7 (Pubitemid 28074354)
31. BarcsG,Walker EB, Elger CE, et al. Oxcarbazepine placebocontrolled, dose-ranging trial in refractory partial epilepsy. Epilepsia 2000 Dec; 41 (12): 1597-607 (Pubitemid 32002734)
32. Eisai Ltd. Zebinix: summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/emc/medicine/22376/SPC/[Accessed 2011 May 8]
33. Sake JK, Hebert D, Isojärvi J, et al. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs 2010 Dec 1; 24 (12): 1055-68
34. Novy J, Patsalos PN, Sander JW, et al. Lacosamide neurotoxicity associated with concomitant use of sodium channel-blocking antiepileptic drugs: a pharmacodynamic interaction? Epilepsy Behav 2011 Jan; 20 (1): 20-3
35. Brodie MJ, Rosenfeld WE, Vazquez B, et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. Epilepsia 2009 Aug; 50 (8): 1899-909
36. Deckers CL, Czuczwar SJ,Hekster YA, et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 2000 Nov; 41 (11): 1364-74
37. Toledano R, Gil-Nagel A. Adverse effects of antiepileptic drugs. Semin Neurol 2008 Jul; 28 (3): 317-27
38. Ben-Menachem E. Weight issues for people with epilepsy: a review. Epilepsia 2007; 48 Suppl. 9: 42-5 (Pubitemid 350198229)
39. Mohammadianinejad SE, Abbasi V, Sajedi SA, et al. Zonisamide versus topiramate in migraine prophylaxis: a doubleblind randomized clinical trial. Clin Neuropharmacol 2011 Jul-Aug; 34 (4): 174-7
40. Kossoff EH, Pyzik PL, Furth SL, et al. Kidney stones, carbonic anhydrase inhibitors, and the ketogenic diet. Epilepsia 2002 Oct; 43 (10): 1168-71 (Pubitemid 35176123)
41. Mirza NS, Alfirevic A, Jorgensen A, et al. Metabolic acidosis with topiramate and zonisamide: an assessment of its severity and predictors. Pharmacogenet Genomics 2011 May; 21 (5): 297-302
42. Dong X, Leppik IE, White J, et al. Hyponatremia from oxcarbazepine and carbamazepine. Neurology 2005 Dec 27; 65 (12): 1976-8 (Pubitemid 43970125)
43. Rode F, Svalø J, Sheykhzade M, et al. Functional effects of the KCNQ modulators retigabine and XE991 in the rat urinary bladder. Eur J Pharmacol 2010 Jul 25; 638 (1-3): 121-7
44. French JA, Abou-Khalil BW, Leroy RF, et al., RESTORE 1/Study 301 Investigators. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology 2011 May 3; 76 (18): 1555-63